Schizophrenia Clinical Trial
Official title:
A Randomized Double Blind Parallel Trial Administering Methotrexate vs Placebo as add-on to Antipsychotics in Patients With Schizophrenia or Schizoaffecive Disorder
A recent double-blind placebo-controlled study has tested the effect of methotrexate as an
add-on treatment for patients with schizophrenia or schizoaffective disorder, administering
10 mg of methotrexate or placebo once a week for a period of three months to 72 patients
(Chaudry, Husain et al. 2015). Results showed improvement both in positive symptoms, as
measured by the Positive symptoms subscale of the Positive and Negative Syndrome Scale
(PANSS), and in total PANSS scores.
The objective of this study is to replicate Chaudry et al.'s study. This proposed study will
randomize schizophrenia or schizoaffective disorder patients to methotrexate or placebo for a
period of four months.
The study will enroll patients with a DSM-IV-TR diagnosis of schizophrenia or schizoaffective
disorder confirmed by the Modified Structured Clinical Interview for Diagnosis (SCID). In
order to be eligible to enter the study, the patient must have a score of 4 (moderately ill)
or greater on the Clinical Global Impression - Severity (CGI-S) scale. In addition, inclusion
criteria reflect patients with moderate or more severity on positive symptoms, hence having a
score of 4 (moderate) or above on two of the following four PANSS items: delusions,
hallucinatory behaviors, conceptual disorganization or suspiciousness/ persecution. Patients
receiving more than one anti-psychotic or depot antipsychotic will be allowed to participate,
and patients receiving anti-cholinergic agents, beta-blockers, anti-depressants,
mood-stabilizers, sedatives, and anti-anxiety agents will be allowed in the study. Because
the clinical status of patients sometimes improves in the days following admission to the
hospital, newly hospitalized patients will have their baseline visit 3 days or more after
being hospitalized.
OBJECTIVES The objective of the study is to evaluate the efficacy of Methotrexate compared to
placebo, as add-on to anti-psychotics in the treatment of patients with schizophrenia or
schizoaffective disorder.
ENDPOINTS Primary outcome measure: PANSS positive score at the end of the trial. Secondary
outcome measures: PANSS total, negative and general psychopathology scales, Clinical Global
Impression Scale-Severity (CGI-S) and Global Impression Scale-Improvement (CGI-I), Social
Functioning Scale Assessment (PSP) and rates of drop outs before the end of the trial.
DESIGN Randomized, add-on to anti-psychotics, double blind, placebo-controlled trial.
ASSESSMENTS
- Positive and Negative Syndrome Scale (PANSS). PANSS is a 30-item rating scale widely
used in assessment of medication effects in schizophrenia.
- Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement
(CGI-I). CGI-S and CGI-I will be used to assess severity of the illness and global
improvement.
- The Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale: will be used to
assess commonly occurring side effects caused by anti-psychotics.
- The methotrexate toxicity checklist includes rash, oral ulceration, nausea and vomiting,
diarrhea, new or increasing dyspnea, new or increasing dry cough, severe sore throat,
and abnormal bruising.
- The Personal and Social Performance (PSP) scale will be used to assess social
functioning.
PROCEDURE At the screening visit informed consent will be obtained, inclusion and exclusion
criteria will be examined, and demographic information will be collected. The PANSS, CGI-S
and SCID assessment will be administered, a physical examination will be done, psychiatric
and medical history obtained, and blood samples for chemistry and CBC, and urine samples for
urinalysis will be taken. Patients will liver function levels higher than normal will be
excluded. Females of child-bearing potential will be tested for pregnancy. Patients will be
screened for HIV, Hepatitis B and C.
At the baseline visit, The PANSS, CGI-S, UKU, and PSP will be administered. Patients will be
randomized to start study medication: Methotrexate 10 mg/week or equivalent dose of placebo
will be administered to patients. Medication dose will start at 10mg for the first two weeks
and will then be increased to 15 mg. Patients will also be instructed to take 5 mg/day of
folic acid for 6 days/week in order to avoid vitamin deficiencies due to the methotrexate
use. In order to monitor potential side-effects, blood tests for CBC and SMA will be taken at
screening, week 2, week 4, week 8, week 12, and week 16 (EOS).
Subjects will be assessed at clinic visits according to timelines described above.
Additionally, during the weeks in which patients will not come for clinic visits, they will
have phone visits in order to monitor medication adherence and adverse events. Throughout all
the visits between baseline and end of study, patients will be checked for methotrexate
toxicity using the methotrexate toxicity checklist which inquires for includes rash, oral
ulceration, nausea and vomiting, diarrhea, new or increasing dyspnea, new or increasing dry
cough, severe sore throat, and abnormal bruising.
A final, End-of-Study, clinical evaluation will occur on Week 16, or at the time of early
discontinuation from the study, and will include a physical examination; vital signs; rating
of the PANSS, CGI-S, CGI-I, UKU, PSP, review of adverse events, methotrexate toxicity
checklist and concomitant medications. Blood samples will be taken for SMA, CBC, and urine
samples for urinalysis. Females of child-bearing potential will be tested for pregnancy, and
a blood sample for medication levels will be taken.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |